NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee C) meeting minutes

**Minutes:** Confirmed

**Date and Time:** Wednesday 18 March 2020

## Committee members present:

Peter Selby (Chair) Present for all notes

Stephen O’Brien (Chair) Present for all notes

Alex Cale Present for all notes

Andrew Renehan Present for notes 1 to 12

David Foreman Present for all notes

Iain McGowan Present for all notes

John Hampson Present for all notes

Matt Stevenson Present for all notes

Michael Chambers Present for all notes

Mudasar Mushtaq Present for all notes

Natalie Hallas Present for all notes

Nigel Langford Present for all notes

Paul Tappenden Present for all notes

Richard Nicholas Present for all notes

Rob Forsyth Present for all notes

Stella O’Brien Present for all notes

Ugochi Nwulu Present for notes 1 to 7

## NICE Staff Present:

Helen Knight, Programme Director, National Institute for Health and Care Excellence

Present for all notes

Frances Sutcliffe, Associate Director, National Institute for Health and Care Excellence

Present for all notes

Louise Jafferally, Project Manager, National Institute for Health and Care Excellence

Present for all notes

Pratit Shah, Administrator, National Institute for Health and Care Excellence

Present for all notes

Anita Sangha, Technical Analyst, National Institute for Health and Care Excellence

Present for notes 1 to 7

Alexandra Filby, Technical Adviser, National Institute for Health and Care Excellence

Present for notes 1 to 12

Vicki Pollit, Technical Analyst, National Institute for Health and Care Excellence

Present for notes 8 to 12

Jamie Elvidge, Technical Adviser, National Institute for Health and Care Excellence

Present for notes 13 to 17

Abi Senthinathan, Technical Analyst, National Institute for Health and Care Excellence

Present for notes 13 to 17

## Non-Public members present:

Robert Wolff, ERG representative Present for notes 1 to 4.3

Maiwenn Al, ERG representative Present for notes 1 to 4.3

Sophie Beale , ERG representative Present for notes 8 to 9.3 & 13 to 14.3

James Mahon, ERG representative Present for notes 8 to 9.3 & 13 to 14.3

Andrew Davies, Clinical expert Present for notes 1 to 4.3

Steve Williamson, CDF clinical lead Present for notes 8 to 9.3 & 13 to 14.3

Sarah Bromley, NICE observer Present for all notes

Adam Storrow, NICE observer Present for all notes

Charlie Hewitt, NICE observer Present for all notes

Ewa Rupniewska, NICE observer Present for all notes

James Fitton, NICE observer Present for notes 8 to 12

Eun-Young Bae, External observer Present for all notes

Cameron Collins, External observer Present for all notes

Samuel Harper, External observer Present for notes 8 to 17

## Notes

### Any other Business

1. None

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 18 February 2020.

### Appraisal of Naldemedine for treating opioid-induced constipation [ID1189]

**Part 1 – Open session**

1. The Chair welcomed the invited clinical expert, Evidence Review Group (ERG) representatives and representatives from Shionogi Ltd.
2. The Chair asked all committee members, clinical expert, ERG representatives and NICE staff present to declare any relevant interests  
   1. Richard Nicholas declared a non-personal non-specific financial interest as he received consultancy fee for taking part in an advisory board for a drug on Multiple Sclerosis for a comparator company, Novartis Pharmaceuticals. However, this is for an unrelated topic for this appraisal.
      1. It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
   2. Andrew Davies declared a non-personal specific financial interest as he has participated in consultancy work for Kyowa Kirin on the drug, Naloxegol, which is a comparator drug to this appraisal. Andrew Davies has participated in consultancy work for Sandoz which is a comparator company to this appraisal. Andrew Davies declared a non-personal specific non-financial interest as he is the Chair of a guideline group for the management of constipation in patients with advanced cancer at the Multi-national Association of Supportive Care in Cancer. Andrew Davies has received honoraria for participating in advisory boards from companies that market PAMORAs, such as AstraZeneca, Kyowa Kirin, Shionogi and Wyeth.
      1. It was agreed that the declarations would not prevent Andrew Davies from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.

## Part 2 – Closed session (company representatives, clinical expert, ERG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Nivolumab for previously treated squamous non-small-cell lung cancer (CDF review TA483) [ID1559]

### Part 1 – Open session

1. The Chair welcomed the invited NHS commissioning expert, Evidence Review Group (ERG) representatives and representatives from Bristol Myers-Squibb Pharmaceuticals.
2. The Chair asked all committee members, ERG and NICE staff present to declare any relevant interests  
   1. Richard Nicholas declared a non-personal non-specific financial interest as he received consultancy fee for taking part in an advisory board for a drug on Multiple Sclerosis a comparator company, Novartis Pharmaceuticals. However, this is for an unrelated topic for this appraisal.
      1. It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
   2. Michael Chambers declared a non-personal non-specific financial interest as he received consultancy fee by a comparator company, Roche Products in an unrelated disease area to this appraisal.
      1. It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session (company representatives, NHS commissioning expert, ERG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

### Part 1 – Open session

1. The Chair welcomed the invited NHS commissioning expert, Evidence Review Group (ERG) representatives and representatives from Bristol Myers-Squibb Pharmaceuticals.
2. The Chair asked all committee members, NHS commissioning expert, ERG representatives and NICE staff present to declare any relevant interests  
   1. Richard Nicholas declared a non-personal non-specific financial interest as he received consultancy fee for taking part in an advisory board for a drug on Multiple Sclerosis a comparator company, Novartis Pharmaceuticals. However, this is for an unrelated topic for this appraisal.
      1. It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
   2. Michael Chambers declared a non-personal non-specific financial interest as he received consultancy fee by a comparator company, Roche Products in an unrelated disease area to this appraisal.
      1. It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session (company representatives, NHS commissioning expert, ERG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Next Committee Meeting:**

**Wednesday 8 April 2020** at **10am**. The meeting will be held at Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, United Kingdom